Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Our aim was to investigate the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane alone followed by tailored treatment, either continued exemestane monotherapy or exemestane plus docetaxel–cyclophosphamide (TC) combination therapy, in postmenopausal patients with primary in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Med
Asıl Yazarlar: Sato, Nobuaki, Masuda, Norikazu, Morimoto, Takashi, Ueno, Takayuki, Kanbayashi, Chizuko, Kaneko, Koji, Yasojima, Hiroyuki, Saji, Shigehira, Sasano, Hironobu, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Clinical Cancer Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6745863/
https://ncbi.nlm.nih.gov/pubmed/31361400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2423
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller